BIIB Secures FDA Nod for Monthly Maintenance Dosing of Alzheimer's Drug

Biogen (BIIB) announced that the FDA has approved a monthly maintenance dosing version for its intravenously (IV) administered Alzheimer's disease (AD) drug, Leqembi.Post the FDA approval, patients have the option to transition to a monthly maintenance dosing regimen of Leqembi after completing an 18-month course of biweekly infusions of the drug. Alternatively, patients can also opt to continue with the biweekly dosing regimen.The new option provides relief to AD patients taking Leqembi, as IV administrati ...